Literature DB >> 6458777

Citrobacter meningitis and cerebral abscess in early infancy: cure by moxalactam.

R L Levy, R L Saunders.   

Abstract

A 7-week-old boy developed multiple cerebral abscesses as a complication of neonatal Citrobacter diversus meningitis. He was successfully treated medically with the experimental beta-lactam antibiotic, moxalactam. This is the first nonsurgical cure of brain abscess in early infancy. Fifty-eight percent of all previously reported cases of Citrobacter meningitis were complicated by brain abscess, mandating early, and serial computed tomography scanning in patients afflicted with the disorder. Moxalactam may become the chemotherapeutic agent of choice for the treatment of this serious neonatal infection.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6458777     DOI: 10.1212/wnl.31.12.1575

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  6 in total

1.  Citrobacter sepsis in infants.

Authors:  R P Sugandhi; V K Beena; P G Shivananda; M Baliaga
Journal:  Indian J Pediatr       Date:  1992 May-Jun       Impact factor: 1.967

2.  Aspiration or extirpation in cerebral abscess surgery?

Authors:  M Kala
Journal:  Neurosurg Rev       Date:  1993       Impact factor: 3.042

3.  Epidemiologic marker system for Citrobacter diversus using outer membrane protein profiles.

Authors:  M W Kline; E O Mason; S L Kaplan
Journal:  J Clin Microbiol       Date:  1989-08       Impact factor: 5.948

4.  Pathophysiology of Citrobacter diversus neonatal meningitis: comparative studies in an infant mouse model.

Authors:  A L Soriano; R G Russell; D Johnson; R Lagos; I Sechter; J G Morris
Journal:  Infect Immun       Date:  1991-04       Impact factor: 3.441

5.  Citrobacter brain abscesses in neonates: early surgical intervention and review of the literature.

Authors:  Shakeel A Chowdhry; Alan R Cohen
Journal:  Childs Nerv Syst       Date:  2012-04-15       Impact factor: 1.475

Review 6.  Moxalactam (latamoxef). A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  A A Carmine; R N Brogden; R C Heel; J A Romankiewicz; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-10       Impact factor: 9.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.